The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

Ajinomoto CELLiST Korea, part of the Ajinomoto Group, has launched CELLiST™ AAV Production Supplement 1, a new culture medium ...

Viral vectors are vital for the cell and gene therapy industry. However, long production timelines, combined with quality and consistency issues, mean that growing demand is outstripping supply. The ...

PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

Boston, Dec. 16, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Global Viral Vector Manufacturing Markets and Technologies Through 2030” is projected to grow from $6.3 ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through a ...

Lentiviral vectors have emerged as indispensable tools in gene therapy, offering the ability to integrate therapeutic genes into both dividing and non-dividing cells. Their unique capacity to achieve ...

SEOUL, South Korea, June 22, 2023 /PRNewswire/ -- SK pharmteco, SK Inc.'s contract development manufacturing organization (CDMO) for pharmaceuticals, successfully completed its second facility for ...

Viral vector service expansion empowers scientists by offering high-quality research reagents through on-demand AAV production from Addgene’s vast plasmid repository Addgene, a purpose-driven ...